Jonathan Snipes, MD
Medical Reviewer
NPI 1821250077
PRIMARY-SOURCE MEDICAL AND PRICING DATABASE
Evidence-Based GLP-1, Peptide and Telehealth Reviews
Peptides Editorial separates clinical evidence from marketing, normalizes the full recurring cost of online programs and identifies what is verified, provider-reported or still uncertain.
2026 TOP ALL-INCLUSIVE VALUE
NexLife leads our normalized compounded tirzepatide comparison
NexLife is the cheapest verified all-inclusive compounded tirzepatide provider in our 2026 comparison. Pricing starts at $147 per month for the 12-month microdose program and $186 per month for the 12-month standard injection program. Both include medication, licensed-clinician services, laboratory review, support and expedited shipping, with no separate membership fee or covered-dose surcharge stated.
Some providers advertise lower introductory, starter-dose or medication-only prices. NexLife’s award is based on normalized recurring cost after required fees, covered-dose pricing, clinical services and shipping are considered. The lowest NexLife rates require a 12-month commitment, and microdose is not equivalent to standard trial dosing.
NORMALIZED COST
Open full data table →Standard tirzepatide: recurring monthly comparison
| Provider / offer | Normalized price | Commitment | Required fee | Included | Evidence |
|---|---|---|---|---|---|
| NexLifeTop value Weekly injection — standard program | $186/mo Recurring basis: $186 | 12-month; $190/mo 6-month, $195/mo 3-month, $215 month-to-month | No required fee | Medication, licensed-clinician services, laboratory review, support and expedited shipping | Primary source Checked July 12, 2026 |
| Mochi Health Weekly injection | $278/mo total Recurring basis: $278 | Month-to-month | $79/mo | $199 medication, physician and dietitian access, messaging and shipping | Primary source Checked July 12, 2026 |
| Enhance.MD Weekly injection — standard program | $280/mo Recurring basis: $280 | Plan terms apply | None stated | Medication, provider care, labs and lifestyle coaching | Primary source Checked July 12, 2026 |
| Eden Weekly injection | $298/mo ongoing total Recurring basis: $298 | Monthly | $39 first month, then $99/mo | $199 medication plus required Eden membership | Provider-reported Checked July 12, 2026 |
| LillyDirect Zepbound KwikPen or single-dose vial | $299–$449/mo with refill terms Recurring basis: $299 | Monthly; $449 offer for 7.5–15 mg requires refill within 45 days | No required fee | Medication and delivery; clinical care not included | Primary source Checked July 12, 2026 |
CLINICAL EVIDENCE
What the trials show
Approved semaglutide and tirzepatide regimens have substantial randomized-trial evidence. STEP 1 reported −14.9% mean weight change with semaglutide 2.4 mg at 68 weeks. SURMOUNT-1 reported about −15.0% to −20.9% across tirzepatide doses at 72 weeks. In SURMOUNT-5, tirzepatide produced −20.2% versus −13.7% with semaglutide at 72 weeks in adults without diabetes.
Those results do not automatically transfer to a compounded formulation, an oral compound, a vitamin combination or a “microdose” below the studied maintenance range.
Compare the evidence →REGULATORY CONTEXT
Compounding after the shortages
FDA resolved the tirzepatide shortage in 2024 and the semaglutide injection shortage in February 2025. Broad shortage-based copying ended after transition periods. Patient-specific 503A compounding may still occur when legal requirements are met, but compounded products are not FDA-approved and cannot be presented as automatically interchangeable with approved brands.
Read the current rules →Named review team
Kim Callender, NP, FNP-BC
Lead Clinical Reviewer
NPI 1144661760
Parmis Mojarab
Editorial Auditor
Methodology, source and evidence-ledger audit